Loading clinical trials...
Loading clinical trials...
Evaluation of Safety, Pharmacokinetics and Immunomodulatory Effects of AB103, a CD28 Co-stimulatory Receptor Antagonist, in Patients Diagnosed With Necrotizing Soft Tissue Infections
Conditions
Interventions
AB103
Placebo
Locations
7
United States
University of Southern California Los Angeles
Los Angeles, California, United States
San Francisco General Hospital
San Francisco, California, United States
University of Florida
Gainesville, Florida, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Oregon Health and Science University
Portland, Oregon, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Start Date
December 1, 2011
Primary Completion Date
September 1, 2012
Completion Date
September 1, 2012
Last Updated
August 18, 2021
Lead Sponsor
Atox Bio Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions